Global In Vitro Diagnostics (IVD) Quality Control Market By Type (Serum/Plasma-Based Controls, Whole Blood-Based Controls, Urine-Based Controls), By End User (Hospitals, Clinical Laboratories, Academic & Research Institutes), By Region, and Key Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2021-2031

In Vitro Diagnostics (IVD) is a fast growing, essential segment of the global healthcare system. IVD is used to detect diseases, and can also be used to monitor an individual’s overall health to help cure, treat, or prevent diseases. In vitro diagnostics are medical devices that are used to perform tests on samples such as urine, blood, and tissue that are taken from the human body.

In vitro tests are carried out in laboratories, healthcare facilities, etc. Tests can be performed using a variety of instruments ranging from small, handheld tests to complex laboratory instruments.

IVD testing plays a crucial role in clinical decision making. A growing number of accredited clinical laboratories, booming geriatric populations, a steady surge in the demand for external quality assessment programs, the increasing adoption of POC instruments as well as third-party quality controls in developed nations, are major parameters that are anticipated to propel the financial development of the global IVD quality control market over the forecast period.

Detailed Segmentation:

The global IVD quality control market is segmented on the basis of – type, end user, and region. A detailed segmental description is listed below:

Based on Type

• Serum/Plasma-Based Controls
• Whole Blood-Based Controls
• Urine-Based Controls
• Other Types

Based on End User

• Hospitals
• Clinical Laboratories
• Academic & Research Institutes
• Other End users

Based on Key Players

• Bio-Rad Laboratories Inc.
• Randox Laboratories Ltd.
• Thermo Fisher Scientific Inc.
• LGC Limited
• Abbott Laboratories
• Roche Diagnostics
• Siemens Healthineers
• Danaher Corporation
• Fortress Diagnostics
• SERO AS
• Sysmex Corporation
• Ortho-Clinical Diagnostics
• among others.

Based on Region

• North America
• Europe
• Asia-Pacific
• South America
• Middle East and Africa

Market Dynamics

A steady surge in the number of laboratory tests are being carried out across the globe owing to the increasing prevalence of various diseases. In order to cater this demand, there has been significant increase in the number of laboratories in both the public and private sectors. Since December 2019, there has been sudden increase in the demand for diagnostic testing due to the COVID- 19 pandemic.

Several government bodies have set-up new laboratories to increase their respective laboratory testing capacities. These aforementioned factors are anticipated to bolster the revenue growth of the global IVD quality control market over the forecast period.

Incorporating quality control processes in a clinical laboratory requires sizeable investments. In addition, laboratories also need to maintain dedicated personnel to manage their quality control system. This in turn is expected to restrain potential economic growth opportunities to a certain extent for players operating in this industry.

Ongoing technological advancements have led to the development of a new range of multi-analyte and multi-instrument controls, which in turn, are likely to complement revenue expansion prospects for the global IVD quality control market.

Moreover, consistent growth in the GDP of both developed and developing nations has also aided in the evolution of healthcare sector. Owing to this aforementioned growth in GDP, particularly in that of emerging countries, prominent market players have exhibited a keen sense of interest towards these regions.

Competitive Landscape:

Certain key players operating in this global market are – Bio-Rad Laboratories Inc., Randox Laboratories Ltd., Thermo Fisher Scientific Inc., LGC Limited, Abbott Laboratories, Roche Diagnostics, Siemens Healthineers, Danaher Corporation, Fortress Diagnostics, SERO AS, Sysmex Corporation, and Ortho-Clinical Diagnostics, among others. These aforementioned companies develop new products/services, adopt expansion strategies, and undertake partnerships, collaborations, and mergers & acquisitions to gain traction in the global IVD quality control market.

Key Developments:

• In August 2021, Zeptometrix Corporation announced the immediate availability of its ready-to-use NATSARS(COV2)-ERC for laboratory quality control as well as for test validation
• In July 2021, Quidel Corporation received the CE Mark for its innovative Savanna multiplex molecular analyzer as well as for Savanna RVP4 Assay (Respiratory Viral Panel-4)
• In June 2021, LGC SeraCare expanded its line of SARS-CoV-2 molecular quality solutions to include AccuPlex SARS-CoV-2 Variant Panel 1.

For the In Vitro Diagnostics (IVD) Quality Control Market research study, the following years have been considered to estimate the market size: